Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VSA012 injection in lupus nephritis, IgA nephropathy, C3 glomerulopathy and IC-MPGN (Phase II, China)
CTR20260041Phase 2Active
- Sponsor
- Visirna Therapeutics
- Start
- Jan 2026
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of VSA012 in lupus nephritis (LN), systemic lupus erythematosus (SLE), IgA nephropathy (IgAN), Complement 3 glomerulopathy (C3G), membranoproliferative glomerulonephritis (MPGN), sponsored by Visirna Therapeutics. Started Jan 2026; status: active.
02
Drugs
VSA012
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)IgA nephropathy (IgAN)Complement 3 glomerulopathy (C3G)membranoproliferative glomerulonephritis (MPGN)
Beyond the preview
Go deeper on CTR20260041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260041.